Telemedicine

With an increasing demand for cancer care services in a growing population, telemedicine and technology are becoming a vital component of delivering high-quality, value-based cancer care. Innovative e-health platforms and virtual navigation services can improve patient care by mitigating barriers to care for patients who are appropriate for cancer immunotherapy treatment.

Meet the members of the IO Telemedicine Working Group.

Rashid Bashshur
Rashid Bashshur, PhD
Professor Emeritus, Department of Health Management and Policy; Executive Director
UMHS eHealth Center

Rashid L. Bashshur, PhD, is executive director of eHealth at the University of Michigan Health System and emeritus professor of health management and policy at the University of Michigan School of Public Health. Since the early 1970s, he has been a catalyst for the development and evaluation of telemedicine systems in the U.S. He has published extensively on telemedicine, maintains an active speaking schedule, and works closely with policymakers at institutional, state, national, and international levels. In 1994, he cofounded the Telemedicine Journal with Mark Goldberg, and served as senior editor of three reports on telemedicine that were submitted to the U.S. Congress (1994, 1995, and 2001). 

Dr. Bashshur is the recipient of several honors and awards, including the NASA Group Achievement Award; special appreciation from Eastman Kodak; the University of Arizona Founders Award; recognition for service from the American Telemedicine Association; Partners HealthCare Leadership Award; and the Individual Leadership Award for contributions to the development of telemedicine worldwide from the American Telemedicine Association.

Crews- 100x100
Jennie R. Crews, MD, MMM, FACP
Medical Director, Research Integration and SCCA Network
Seattle Cancer Care Alliance
Associate Clinical Professor
University of Washington School of Medicine

Jennie R. Crews, MD, MMM, FACP, is medical director, Seattle Cancer Care Alliance Network; Medical Director, Research Integration at Seattle Cancer Care Alliance (SCCA); and associate professor of Medicine, University of Washington. Dr. Crews has more than 18 years of experience in oncology in academic, private practice, and hospital-based settings. Previously she served as the medical director for Cancer Services in the PeaceHealth Northwest Network, which includes St. Joseph Cancer Center in Bellingham, Washington; PeaceIsland Hospital on San Juan Island, Washington; and PeaceHealth Ketchikan, Alaska. She also served as the medical director of the Marion L. Shepard Cancer Center in Washington, N.C., and held appointments as a consulting associate in the Department of Medicine, Division of Medical Oncology and Transplantation at Duke, and as an affiliate associate professor in the Department of Medicine at East Carolina University.

Dr. Crews served as ACCC Treasurer (2013-2015), ACCC President-Elect (2015-2016), and ACCC President (2016-2017). She has served as the president of the North Carolina Oncology Association (NCOA) and as NCOA’s legislative liaison to the North Carolina General Assembly. She is on the Editorial Committee for the ACCC Oncology Drug Database, a reviewer for the Journal of Oncology Practice, and a member of the ASCO Practice Guidelines Implementation Network. She has been named to the Best Doctors in America since 2007.

Dr. Crews received her BS degree in Biology with highest honors from the University of North Carolina at Chapel Hill. She earned her MD from Duke University and completed training in internal medicine and oncology at Duke, where she served as assistant chief resident. She is a Fellow in the American College of Physicians and is board certified in internal medicine and medical oncology.

Kamal Jethwani MD
Kamal Jethwani, MD, MPH
Senior Director, Partners Connected Health Innovation
Assistant Professor,Harvard Medical School

Kamal Jethwani, MD, MPH, is senior director of Partners Connected Health Innovation (CHI), where he is responsible for leading a multidisciplinary team to identify and solve challenges in healthcare delivery using innovative technology-based solutions.

The core focus of Dr. Jethwani’s research is in facilitating better care delivery through connected health programs by enabling improved patient engagement, patient-provider communication, and patient satisfaction with care. So far, his research has shown that programs which are personalized to each patient’s unique psychology and needs, forge higher engagement and in turn better outcomes. Dr. Jethwani continues to develop analytic and programmatic modalities to improve the understanding of personalization concepts to connected health. He has worked extensively with sensor technology, wearables, and mobile devices as well as social media to deliver care to patients.

Jennifer King
Jennifer King, PhD
Director of Science and Research
Lung Cancer Alliance

Jennifer C. King, PhD, is the director of science and research for the Lung Cancer Alliance. She is a cancer research scientist turned patient advocate who offers a unique perspective, striking a balance between understanding the impact and mechanisms of new treatments and being able to explain what it all means to the greater cancer community. She uses her training to lead cutting-edge research initiatives to improve the lives of those living with or at risk for lung cancer.

Dr. King is a sought-after expert serving as the primary scientific spokesperson for Lung Cancer Alliance and has appeared in the Chicago Tribune, Newsday, CURE, and The Lancet addressing a wide range of cancer-related topics.

She co-founded SHARE For Cures, a nonprofit empowering the patient community to use their individual health data to advance medical research and save lives. As a translational oncology researcher, she studied new molecular targets for cancer therapeutics and developed mouse models while working at Memorial Sloan Kettering Cancer Center and the UCLA Jonsson Comprehensive Cancer Center.

Junaid Razzak
Junaid Razzak, MBBS, MD, PhD
Professor, Director of Telemedicine
Department of Emergency Medicine, Johns Hopkins University

Junaid Razzak, MBBS, MD, PhD, is a professor in the Department of Emergency Medicine at Johns Hopkins University. He recently served as the founding chair of the Department of Emergency Medicine; and founding director of the World Health Organization Collaborating Center at Aga Khan University in Karachi, Pakistan. Dr. Razzak was also the founding member of the Aman Healthcare Services—a nonprofit organization in Karachi—serving as its CEO. He played a pivotal role in the establishment of emergency medicine as a specialty in Pakistan, starting the first advanced life support service in Karachi and helping launch the largest health call center in Pakistan.

Dr. Razzak’s current research focuses on implementing and measuring health system innovations for enhancing access to emergency healthcare for vulnerable populations, especially in the low- and middle-income countries. As director of telemedicine in the emergency medicine department, Dr. Razzak is leading an innovative clinical and research program on the use of technology in improving access to emergency care.

Insights from this working group

  • Telehealth: Partner in Innovation
    By Jennie R. Crews, MD, MMM, FACP
    At ASCO 2018, Fabrice Denis, MD, PhD, presented data showing improved survival in lung cancer patients who tracked their post-treatment symptoms using patient-reported outcomes (PROs). However, during the discussion session, speakers acknowledged that current PROs do not capture symptoms specific to IO. This gap presents an opportunity to explore telehealth solutions that help providers and patients manage IO treatment.
  • IO Patients in the Emergency Department
    By Junaid Razzak, MBBS, MD, PhD

    Emergency physicians are partners in providing care to your acutely ill patients. Since emergency physicians’ experience with and exposure to the novel immunotherapies is relatively limited, it is important that ED physicians and nurses are aware of the indications for these agents and informed on potential acute and chronic complications of immunotherapy for cancer.